EP 0502105 A4 19930224 - NON-REPLICATING RECOMBINANT-MADE RETROVIRAL PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS
Title (en)
NON-REPLICATING RECOMBINANT-MADE RETROVIRAL PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS
Publication
Application
Priority
US 43920589 A 19891120
Abstract (en)
[origin: WO9107425A1] Nonreplicating recombinant-made retroviral particles having structural, morphological and immunological characteristics very similar to those of native human retroviruses are described. The method of the invention involves coexpression of mature retroviral core and envelope structural proteins in mammalian host cells such that the expressed retroviral proteins associate into assembled budding retroviral particles. In a particular embodiment of the invention, nonreplicating recombinant-made HIV-1 particles are produced by coinfecting mammalian host cells with a recombinant vaccinia virus carrying the Human Immunodeficiency Virus Type 1 (HIV-1) gag and protease genes and a recombinant vaccinia virus carrying the HIV-1 env gene. These nonreplicating recombinant-made HIV-1 particles have immunological and morphological characteristics closely resembling those of native HIV-1, are able to block the infectivity of live HIV in vitro, and are highly immunogenic in vivo. The recombinant-made HIV-1 particles of the invention may be used as anti-viral agents and as immunogens in vaccine formulations effective at inhibiting or preventing infection by HIV and/or the development of the Acquired Immunodeficiency Syndrome.
IPC 1-7
IPC 8 full level
A61K 39/21 (2006.01); C07K 14/005 (2006.01); C07K 14/15 (2006.01); C07K 14/155 (2006.01); C07K 14/16 (2006.01); C07K 14/195 (2006.01); C07K 14/705 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01); A61K 39/00 (2006.01); C12R 1/91 (2006.01)
CPC (source: EP KR US)
C07K 1/00 (2013.01 - KR); C07K 14/005 (2013.01 - EP); A61K 39/00 (2013.01 - EP KR US); C12N 2740/16122 (2013.01 - EP)
Citation (search report)
- [X] EP 0241239 A2 19871014 - US COMMERCE [US]
- [XP] EP 0381146 A1 19900808 - BANYU PHARMA CO LTD [JP]
- [XP] EP 0386882 A1 19900912 - DANA FARBER CANCER INST INC [US]
- [E] WO 9105864 A1 19910502 - CONNAUGHT LAB [CA]
- [E] WO 9105860 A1 19910502 - WHITEHEAD BIOMEDICAL INST [US]
- [X] VIROLOGY vol. 160, no. 2, 1987, pages 323 - 329 H. GENDELMAN ET AL. 'Molecular characterisation of a polymerase mutant human HIV'
- [X] J. VIROL. vol. 63, no. 6, 1989, pages 2550 - 2556 C. PENG ET AL. 'Role of hiv type 1 specific protease'
- [X] PROC. NATL. ACAD. SCI. USA vol. 86, no. 22, 1989, pages 8964 - 8967 V. KARAKOSTAS 'HIV-like particles produced by a vaccinia virus expression vector'
- [YO] AIDS RES. HUM. RETROVIRUSES vol. 6, no. 1, 1990, page 63 V. KARAKOSTAS 'Assembly of retrovitus particles lacking env protein in cells infected with recombinant vaccinia virus expressing the HIV1'
- [XP] J. VIROL. vol. 64, no. 6, 1990, pages 2653 - 2659 O. HAFFAR ET AL. 'HIV-like nonreplicating gag-env particles assemble in a recombinant vaccinia virus expression system'
- See also references of WO 9107425A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DOCDB simple family (publication)
WO 9107425 A1 19910530; AU 636944 B2 19930513; AU 6905591 A 19910613; CA 2068713 A1 19910521; EP 0502105 A1 19920909; EP 0502105 A4 19930224; ES 2052478 T1 19940716; FI 922277 A0 19920519; FI 922277 A 19920519; GR 930300005 T1 19930428; HU 9201659 D0 19920828; HU T60506 A 19920928; JP H05503629 A 19930617; KR 920703639 A 19921218; NO 921969 D0 19920519; NO 921969 L 19920626; OA 09698 A 19930830; TW 216446 B 19931121; ZA 909302 B 19910925
DOCDB simple family (application)
US 9006798 W 19901120; AU 6905591 A 19901120; CA 2068713 A 19901120; EP 91900526 A 19901120; ES 91900526 T 19901120; FI 922277 A 19920519; GR 930300005 T 19930428; HU 165990 A 19901120; JP 50108291 A 19901120; KR 920701189 A 19920520; NO 921969 A 19920519; OA 60209 A 19920519; TW 80100246 A 19910112; ZA 909302 A 19901120